Neurocrine Biosciences (FRA:NB3) EPS (Basic): €5.76 (TTM As of Mar. 2026)


FRA:NB3 Neurocrine Biosciences Inc FRA:NB3
95 GF Score
Price €141.20
GF Value €158.95
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Neurocrine Biosciences EPS (Basic)?

Neurocrine Biosciences FRA:NB3 +0.93% 95 EPS (Basic) is €5.76 as of Mar. 2026. GuruFocus rates FRA:NB3 with a GF Score™ of 95/100 and a GF Value™ of €158.95 (Modestly Undervalued). The stock has 6 warning signs investors should review.

Neurocrine Biosciences's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was €1.70. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was €5.76.

Neurocrine Biosciences's EPS (Diluted) for the three months ended in Mar. 2026 was €1.65. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was €5.57.

Neurocrine Biosciences's EPS without NRI for the three months ended in Mar. 2026 was €1.68. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 5.55.

During the past 12 months, Neurocrine Biosciences's average EPS without NRIGrowth Rate was 33.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was 22.60% per year. During the past 5 years, the average EPS without NRI Growth Rate was 18.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Neurocrine Biosciences's highest 3-Year average EPS without NRI Growth Rate was 157.70% per year. The lowest was -58.60% per year. And the median was -0.25% per year.

Neurocrine Biosciences  (FRA:NB3) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Neurocrine Biosciences EPS (Basic) Related Terms

Neurocrine Biosciences EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Neurocrine Biosciences's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neurocrine Biosciences EPS (Basic) Chart

Neurocrine Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.84 1.52 2.35 3.25 4.11

Neurocrine Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.07 0.95 1.80 1.32 1.70
FRA:NB3
95GF Score
Neurocrine Biosciences Inc FRA:NB3
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Neurocrine Biosciences EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Neurocrine Biosciences's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(408.724-0)/99.500
=4.11

Neurocrine Biosciences's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(171.183-0)/100.500
=1.70

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €5.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €5.76 mean?
Neurocrine Biosciences (FRA:NB3) has a EPS (Basic) of €5.76 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Neurocrine Biosciences and its competitors.
Is Neurocrine Biosciences' EPS (Basic) too high?
Neurocrine Biosciences' current EPS (Basic) is €5.76. Overall, Neurocrine Biosciences has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Neurocrine Biosciences' EPS (Basic) compare to VTRS and ELAN?
Neurocrine Biosciences' EPS (Basic) of €5.76 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Neurocrine Biosciences and its competitors. Neurocrine Biosciences's current EPS (Basic) is €5.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neurocrine Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Neurocrine Biosciences (FRA:NB3) is currently considered Modestly Undervalued. The stock's GF Value™ is €158.95, compared to a current price of €141.20 — trading 11.2% below its estimated fair value. The current EPS (Basic) is €5.76. Neurocrine Biosciences' overall GF Score™ is 95/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Neurocrine Biosciences (FRA:NB3), the current EPS (Basic) is €5.76 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Neurocrine Biosciences (FRA:NB3) Overvalued in 2026?

Based on GuruFocus' analysis, Neurocrine Biosciences stock appears to be undervalued. The current stock price of €141.20 is trading 11.2% below its estimated GF Value™ of €158.95. GuruFocus considers Neurocrine Biosciences to be Modestly Undervalued.

Key valuation signals for FRA:NB3:

  • EPS (Basic): €5.76
  • GF Value™: €158.95 vs. price of €141.20 (11.2% below fair value)
  • GF Score™: 95/100 with 6 warning signs

No single metric tells the full story. See the FRA:NB3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Neurocrine Biosciences Business Description

Address 6027 Edgewood Bend Court, San Diego, CA, USA, 92130
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
95GF Score

Get the complete analysis for FRA:NB3

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€141.20
Price
€158.95
GF Value